Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 2/20 | 0.61 |
| ▸ | PAK4 | O96013 | 2/20 | 0.61 |
| ▸ | AURKA | O14965 | 13/20 | 0.48 |
| ▸ | GSK3B | P49841 | 10/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.47 |
| ▸ | SRC | P12931 | 5/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.46 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073719 | 0.80 | PAK4 (0.48) | PAK4GSK3BSRCNTRK1 | |
| SCHEMBL785406 | 0.80 | AURKA (0.70) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL30147253 | 0.80 | AURKA (0.70) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL30147254 | 0.79 | AURKA (0.71) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL22054562 | 0.79 | AURKA (0.71) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL22054198 | 0.77 | PLK4 (0.62) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL22055218 | 0.77 | NTRK1 (0.59) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL30147250 | 0.77 | NTRK1 (0.59) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL4184328 | 0.76 | PLK4 (0.61) | PLK4PAK4AURKAGSK3BAURKB | |
| SCHEMBL24996468 | 0.75 | PLK4 (0.63) | PLK4PAK4AURKAGSK3BAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247554-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2007117995-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247554-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | PLK4 290/4885PAK4 150/4885AURKA 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.